vs
Shift4 Payments, Inc.（FOUR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Shift4 Payments, Inc.的季度营收约是Revvity的1.5倍（$1.2B vs $772.1M），Revvity净利率更高（12.7% vs 3.4%，领先9.4%），Shift4 Payments, Inc.同比增速更快（34.0% vs 5.9%），Shift4 Payments, Inc.自由现金流更多（$222.5M vs $161.8M），过去两年Shift4 Payments, Inc.的营收复合增速更高（29.6% vs 9.0%）
Shift4 Payments是美国支付处理服务商，总部位于宾夕法尼亚州阿伦敦，1999年由贾里德·艾萨克曼创立。公司为零售、酒店、休闲、餐饮等行业超20万家商户提供支付处理服务，主营移动支付软硬件等商业技术，2020年于纽约证券交易所挂牌上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FOUR vs RVTY — 直观对比
营收规模更大
FOUR
是对方的1.5倍
$772.1M
营收增速更快
FOUR
高出28.2%
5.9%
净利率更高
RVTY
高出9.4%
3.4%
自由现金流更多
FOUR
多$60.7M
$161.8M
两年增速更快
FOUR
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $772.1M |
| 净利润 | $40.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 10.8% | 14.5% |
| 净利率 | 3.4% | 12.7% |
| 营收同比 | 34.0% | 5.9% |
| 净利润同比 | -65.3% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FOURRVTY
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $966.2M | $720.3M | ||
| Q1 25 | $848.3M | $664.8M | ||
| Q4 24 | $887.0M | $729.4M | ||
| Q3 24 | $909.2M | $684.0M | ||
| Q2 24 | $827.0M | $691.7M | ||
| Q1 24 | $707.4M | $649.9M |
净利润FOURRVTY
| Q4 25 | $40.2M | $98.4M | ||
| Q3 25 | $28.1M | $46.7M | ||
| Q2 25 | $34.0M | $53.9M | ||
| Q1 25 | $16.7M | $42.2M | ||
| Q4 24 | $116.0M | $94.6M | ||
| Q3 24 | $53.8M | $94.4M | ||
| Q2 24 | $39.2M | $55.4M | ||
| Q1 24 | $20.6M | $26.0M |
毛利率FOURRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FOURRVTY
| Q4 25 | 10.8% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 8.6% | 12.6% | ||
| Q1 25 | 3.0% | 10.9% | ||
| Q4 24 | 9.7% | 16.3% | ||
| Q3 24 | 8.8% | 14.3% | ||
| Q2 24 | 7.2% | 12.4% | ||
| Q1 24 | 3.0% | 6.8% |
净利率FOURRVTY
| Q4 25 | 3.4% | 12.7% | ||
| Q3 25 | 2.4% | 6.7% | ||
| Q2 25 | 3.5% | 7.5% | ||
| Q1 25 | 2.0% | 6.4% | ||
| Q4 24 | 13.1% | 13.0% | ||
| Q3 24 | 5.9% | 13.8% | ||
| Q2 24 | 4.7% | 8.0% | ||
| Q1 24 | 2.9% | 4.0% |
每股收益（稀释后）FOURRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.0M | $919.9M |
| 总债务越低越好 | $4.5B | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $8.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 3.15× | — |
8季度趋势，按日历期对齐
现金及短期投资FOURRVTY
| Q4 25 | $964.0M | $919.9M | ||
| Q3 25 | $1.5B | $931.4M | ||
| Q2 25 | $3.0B | $991.8M | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.4B | $1.2B | ||
| Q2 24 | $205.0M | $2.0B | ||
| Q1 24 | $522.9M | $1.7B |
总债务FOURRVTY
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $3.7B | — | ||
| Q1 25 | $2.8B | — | ||
| Q4 24 | $2.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FOURRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $805.2M | $7.6B | ||
| Q4 24 | $806.6M | $7.7B | ||
| Q3 24 | $811.8M | $7.9B | ||
| Q2 24 | $700.8M | $7.9B | ||
| Q1 24 | $674.5M | $7.8B |
总资产FOURRVTY
| Q4 25 | $8.7B | $12.2B | ||
| Q3 25 | $9.0B | $12.1B | ||
| Q2 25 | $7.0B | $12.4B | ||
| Q1 25 | $5.0B | $12.4B | ||
| Q4 24 | $5.0B | $12.4B | ||
| Q3 24 | $5.0B | $12.8B | ||
| Q2 24 | $3.5B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
负债/权益比FOURRVTY
| Q4 25 | 3.15× | — | ||
| Q3 25 | 2.83× | — | ||
| Q2 25 | 2.34× | — | ||
| Q1 25 | 3.53× | — | ||
| Q4 24 | 3.52× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $222.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 18.7% | 21.0% |
| 资本支出强度资本支出/营收 | 0.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.56× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $624.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FOURRVTY
| Q4 25 | $223.7M | $182.0M | ||
| Q3 25 | $171.8M | $138.5M | ||
| Q2 25 | $141.9M | $134.3M | ||
| Q1 25 | $96.6M | $128.2M | ||
| Q4 24 | $145.4M | $174.2M | ||
| Q3 24 | $182.1M | $147.9M | ||
| Q2 24 | $116.1M | $158.6M | ||
| Q1 24 | $56.7M | $147.6M |
自由现金流FOURRVTY
| Q4 25 | $222.5M | $161.8M | ||
| Q3 25 | $165.4M | $120.0M | ||
| Q2 25 | $141.0M | $115.5M | ||
| Q1 25 | $95.1M | $112.2M | ||
| Q4 24 | $143.8M | $149.8M | ||
| Q3 24 | $180.1M | $125.6M | ||
| Q2 24 | $113.9M | $136.6M | ||
| Q1 24 | $55.4M | $129.7M |
自由现金流率FOURRVTY
| Q4 25 | 18.7% | 21.0% | ||
| Q3 25 | 14.1% | 17.2% | ||
| Q2 25 | 14.6% | 16.0% | ||
| Q1 25 | 11.2% | 16.9% | ||
| Q4 24 | 16.2% | 20.5% | ||
| Q3 24 | 19.8% | 18.4% | ||
| Q2 24 | 13.8% | 19.7% | ||
| Q1 24 | 7.8% | 20.0% |
资本支出强度FOURRVTY
| Q4 25 | 0.1% | 2.6% | ||
| Q3 25 | 0.5% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.3% | 3.2% | ||
| Q1 24 | 0.2% | 2.7% |
现金转化率FOURRVTY
| Q4 25 | 5.56× | 1.85× | ||
| Q3 25 | 6.11× | 2.97× | ||
| Q2 25 | 4.17× | 2.49× | ||
| Q1 25 | 5.78× | 3.03× | ||
| Q4 24 | 1.25× | 1.84× | ||
| Q3 24 | 3.38× | 1.57× | ||
| Q2 24 | 2.96× | 2.87× | ||
| Q1 24 | 2.75× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOUR
| Payments Based Revenue | $788.8M | 66% |
| Other | $255.0M | 21% |
| Subscription And Other Revenues | $144.8M | 12% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
